NCT02213926 2026-02-10
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Acerta Pharma BV
Phase 2 Active not recruiting
Acerta Pharma BV
AstraZeneca
Acerta Pharma BV
Weill Medical College of Cornell University
SCRI Development Innovations, LLC
Washington University School of Medicine
Aprea Therapeutics
AstraZeneca